Journey Medical Corp DERM.OQ DERM.O is expected to show a fall in quarterly revenue when it reports results on March 26 for the period ending December 31 2024
The Scottsdale Arizona-based company is expected to report a 6.8% decrease in revenue to $14.213 million from $15.26 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Journey Medical Corp is $10.00, above its last closing price of $5.74.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.14 | -0.15 | -0.17 | Missed | -15.3 |
Jun. 30 2024 | -0.14 | -0.14 | -0.17 | Missed | -18.6 |
Mar. 31 2024 | -0.23 | -0.23 | -0.53 | Missed | -125.5 |
Dec. 31 2023 | -0.09 | -0.08 | -0.12 | Missed | -56.5 |
Sep. 30 2023 | -0.11 | -0.15 | 0.80 | Beat | 616.1 |
Jun. 30 2023 | -0.35 | -0.33 | -0.29 | Beat | 13.4 |
Mar. 31 2023 | -0.45 | -0.45 | -0.57 | Missed | -27.6 |
Dec. 31 2022 | -0.47 | -0.60 | Missed | -28.6 |
This summary was machine generated March 24 at 20:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。